Life Sciences Market Research Report
Report Filter Reset All
Sort By Price
Published Date
Category
Publishers
Report Type
Continents
Regions
Global A-Methapred Market Insights, Forecast to 2025
A-Methapred (methylprednisolone sodium succinate for injection, USP) sterile powder contains methylprednisolone sodium succinate as the active ingredient. Me...
$3,900.00 22 May, 2019 | QYResearch
Global A-Methapred Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
A-Methapred (methylprednisolone sodium succinate for injection, USP) sterile powder contains methylprednisolone sodium succinate as the active ingr...
Global Eloctate Market Insights, Forecast to 2025
ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. The global Eloc...
$3,900.00 22 May, 2019 | QYResearch
Global Eloctate Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. The g...
Global Acquired hemophilia A Drugs Market Insights, Forecast to 2025
ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. The global Acqu...
$3,900.00 22 May, 2019 | QYResearch
Global Acquired hemophilia A Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. The g...
Global Acquired hemophilia A Treatment Market Insights, Forecast to 2025
ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. The global Acqu...
$3,900.00 22 May, 2019 | QYResearch
Global Acquired hemophilia A Treatment Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. The g...
Global Aldesleukin Market Insights, Forecast to 2025
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleu...
$3,900.00 22 May, 2019 | QYResearch
Global Aldesleukin Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the huma...
Global Proleukin Market Insights, Forecast to 2025
Proleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleuki...
$3,900.00 22 May, 2019 | QYResearch
Global Proleukin Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Proleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human ...
Global Acral Lentiginous Melanoma Drugs Market Insights, Forecast to 2025
Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog ...
$3,900.00 22 May, 2019 | QYResearch
Global Acral Lentiginous Melanoma Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing ...
Global Acral Lentiginous Melanoma Treatment Market Insights, Forecast to 2025
Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog ...
$3,900.00 22 May, 2019 | QYResearch
Global Acral Lentiginous Melanoma Treatment Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing ...
Global Acral Lentiginous Melanoma Market Insights, Forecast to 2025
Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog ...
$3,900.00 22 May, 2019 | QYResearch
Global Acral Lentiginous Melanoma Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing ...
Global Sandostatin LAR Market Insights, Forecast to 2025
Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor ...
$3,900.00 22 May, 2019 | QYResearch
Global Sandostatin LAR Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent ...
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
